Mode
Text Size
Log in / Sign up

Narrative review outlines multimodal diagnostic strategies for Hymenoptera venom allergy and clonal mast-cell disorders.

Narrative review outlines multimodal diagnostic strategies for Hymenoptera venom allergy and clonal …
Photo by Brett Jordan / Unsplash
Key Takeaway
Consider a multimodal, individualized diagnostic strategy integrating clinical context with complementary laboratory and functional tests.

This narrative review addresses the diagnostic landscape for Hymenoptera venom allergy, IgE-mediated anaphylaxis, and clonal mast-cell disorders in exposed individuals. The authors evaluate various diagnostic modalities, including clinical history, skin prick testing, intradermal testing, serum IgE, component-resolved diagnostics, tryptase measurements, functional assays, sting challenge, and novel biomarkers. The scope encompasses the strengths and weaknesses of these tools in predicting reaction severity and confirming clinical reactivity.

The review highlights that clinical history and epidemiologic predictors lack sufficient predictive power when used alone. While skin prick and intradermal testing demonstrate high sensitivity, their interpretation is limited by interspecies cross-reactivity, extract variability, and reduced reliability shortly after a sting. Serum IgE and component-resolved diagnostics can improve species identification but are influenced by cross-reactive carbohydrate determinants and cannot reliably predict reaction severity or venom-immunotherapy outcomes.

Basal and acute tryptase measurements contribute significantly to risk stratification and detection of clonal mast-cell disorders, though normal values do not exclude severe reactions. Functional assays provide dynamic confirmation of effector-cell reactivity in diagnostically challenging cases. Sting challenge remains the reference method for confirming clinical reactivity or protection but is reserved for selected high-risk patients due to inherent procedural risks. Novel biomarkers offer promising avenues for future refinement.

The authors acknowledge limitations such as the inability of normal tryptase values to rule out severe reactions and the procedural risks associated with sting challenge. The practice relevance lies in the evidence supporting a multimodal, individualized diagnostic strategy integrating clinical context with complementary laboratory and functional tests to optimize patient management.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Hymenoptera stings are a major trigger of IgE-mediated anaphylaxis, yet only a minority of exposed individuals develop systemic reactions, making accurate diagnosis essential but complex. This review synthesizes current evidence across clinical, serologic, cellular and molecular diagnostic modalities in Hymenoptera venom allergy. Clinical history and epidemiologic predictors—such as occupation, cumulative sting exposure, reaction latency, comorbidities and quality-of-life impairment, provide crucial context but lack sufficient predictive power when used alone. Skin prick and intradermal testing remain first-line tools due to high sensitivity, although interpretation is limited by interspecies cross-reactivity, extract variability and reduced reliability shortly after a sting. Serum IgE and component-resolved diagnostics improve species identification but are influenced by cross-reactive carbohydrate determinants and cannot reliably predict reaction severity or venom-immunotherapy outcomes. Basal and acute tryptase measurements contribute significantly to risk stratification and detection of clonal mast-cell disorders, though normal values do not exclude severe reactions. Functional assays, including basophil activation testing, histamine-release assays and emerging mast-cell activation platforms, provide dynamic confirmation of effector-cell reactivity in diagnostically challenging cases. Controlled sting challenge remains the reference method for confirming clinical reactivity or protection but is reserved for selected high-risk patients due to inherent procedural risks. Novel biomarkers such as osteopontin, KIT mutations, PGD2 metabolites, regulatory T-cell signatures and multi-omic molecular profiles offer promising avenues for future refinement. Overall, evidence supports a multimodal, individualized diagnostic strategy integrating clinical context with complementary laboratory and functional tests.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.